What Is Acrivon Therapeutics, Inc. (ACRV) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Acrivon Therapeutics, Inc.'s intrinsic value is estimated at $1.03. Trading at its current price of $1.92, the valuation engine raises significant caution: 6 of 7 models flag downside risk, projecting an average implied return of -46.6%. The most optimistic model, PWERM, places fair value at $1.87 (-2.8%), while Bayesian DCF — the most conservative — estimates $0.72 (-62.7%). This +59.9% gap reflects genuine analytical uncertainty about Acrivon Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About ACRV?
7 of 13 models are currently active for ACRV. All 7 active models suggest the stock trades above fair value. The Bayesian DCF estimates ACRV's intrinsic value at $0.72, implying -62.7% downside from the current price. See which stocks rank higher →
How Does ACRV Rank in Biotechnology?
Among 76 Biotechnology stocks, ACRV ranks #56 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Acrivon Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is ACRV a Value Trap?
CirclFi's Value Trap algorithm assigns ACRV a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Acrivon Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Acrivon Therapeutics, Inc. scores 4.3 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +59.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ACRV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ACRV's 7 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad